Abstract
Mucormycosis has recently been recognized as a severe complication of COVID-19 with high fatality rates. We report a fatal case of COVID-19 associated mucormycosis (CAM) in a non-diabetic immunocompromised patient, who was first misdiagnosed and treated for COVID-19 associated aspergillosis (CAPA). The risk factors and initial clinical presentation of CAPA and CAM are similar, but CAM has a more aggressive course and CAPA and CAM are treated differently. Dedicated diagnostic workup is essential to ensure early treatment of CAM with surgical debridement and targeted antifungal therapy.
All Keywords
【저자키워드】 COVID-19, SARS-CoV-2, Immunosuppression, Mucormycosis, Rhizopus microsporum, Invasive fungal infection, 【초록키워드】 surgical, risk factor, Immunocompromised patient, early treatment, fatality, complication of COVID-19, antifungal therapy, initial, diagnostic workup, Course, treated, 【제목키워드】 diagnostic, Immunocompromised, Critical, Pulmonary mucormycosis, mind,
【저자키워드】 COVID-19, SARS-CoV-2, Immunosuppression, Mucormycosis, Rhizopus microsporum, Invasive fungal infection, 【초록키워드】 surgical, risk factor, Immunocompromised patient, early treatment, fatality, complication of COVID-19, antifungal therapy, initial, diagnostic workup, Course, treated, 【제목키워드】 diagnostic, Immunocompromised, Critical, Pulmonary mucormycosis, mind,